As­traZeneca gets a much-need­ed boost for blood thin­ner Bril­in­ta with an OK on stroke

While As­traZeneca’s blood thin­ner Bril­in­ta is far from reach­ing its once-pro­ject­ed $3.5 bil­lion sales peak in car­dio­vas­cu­lar dis­ease, a new ap­proval al­lows the phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER